Clinical Trial Updates From the Gene-Editing Field...
CMN Clinical
Mar. 27, 2024
Relevant Interviews, Webinar and Trial Updates posted by CRISPR Medicine News.
Always stay updated with the free CMN Newsletter.
Regeneron Pharmaceuticals
Main (gene editing) focus: Gene editing for genetic diseases
Company stage: Commercial
Diseases: Transthyretin (ATTR) Amyloidosis, hemophilia A and B, multiple undisclosed
Genome editing tool: CRISPR-Cas9
Funding stage: Public (NASDAQ: REGN)
Location: Tarrytown, NY, USA
Website: https://www.regeneron.com/
Pipeline: https://www.regeneron.com/science/pipeline
Partners: Intellia Therapeutics
Regeneron is a public, large pharma company that has been in operation since 1988. The company is focusing on a broad range of diseases, but has recently struck up a partnership deal with Intellia Therapeutics. Together, the two companies are developing both in vivo and ex vivo based therapies. The most advanced programme, NTLA-2001 is being developed as a one-time, in vivo treatment for Transthyretin (ATTR) Amyloidosis.
Tags
Regeneron Pharmaceuticals, Inc.
Related News and Updates
Clinical Trials
IND Enabling
Phase I
Phase II
Phase III
